BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27216064)

  • 1. Predicting Antibiotic Resistance in Urinary Tract Infection Patients with Prior Urine Cultures.
    Dickstein Y; Geffen Y; Andreassen S; Leibovici L; Paul M
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4717-21. PubMed ID: 27216064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Asakura T; Ikeda M; Nakamura A; Kodera S
    Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram.
    García-Tello A; Gimbernat H; Redondo C; Meilán E; Arana DM; Cacho J; Dorado JF; Angulo JC
    Scand J Urol; 2018 Feb; 52(1):70-75. PubMed ID: 28893132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
    Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
    Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Doi A; Shimada T; Harada S; Iwata K; Kamiya T
    Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
    Kim SA; Altshuler J; Paris D; Fedorenko M
    Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-Spectrum beta (β)-Lactamases and Antibiogram in Enterobacteriaceae from Clinical and Drinking Water Sources from Bahir Dar City, Ethiopia.
    Abera B; Kibret M; Mulu W
    PLoS One; 2016; 11(11):e0166519. PubMed ID: 27846254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
    Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S
    World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
    Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
    Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of multidrug resistant Enterobacteriaceae isolated from outpatient urine samples but not the hospital environment in Bo, Sierra Leone.
    Leski TA; Taitt CR; Bangura U; Stockelman MG; Ansumana R; Cooper WH; Stenger DA; Vora GJ
    BMC Infect Dis; 2016 Apr; 16():167. PubMed ID: 27090787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
    de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
    Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the ChromID ESBL agar for the detection of ESBL-positive Enterobacteriaceae and vancomycin-resistant enterococcus isolates from urine cultures].
    Alışkan HE; Colakoğlu S; Turunç T; Demiroğlu YZ
    Mikrobiyol Bul; 2012 Jan; 46(1):17-25. PubMed ID: 22399167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncarbapenems for the Treatment of Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Bacteria.
    White CW; Kyle JA; Deas CM; Campbell J
    South Med J; 2019 Aug; 112(8):438-443. PubMed ID: 31375841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bahrain.
    Bindayna KM; Senok AC; Jamsheer AE
    J Infect Public Health; 2009; 2(3):129-35. PubMed ID: 20701872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Delory T; Gravier S; Le Pluart D; Gaube G; Simeon S; Davido B; Piet E; Lepeule R; Lesprit P; Lafaurie M
    Int J Antimicrob Agents; 2021 Jul; 58(1):106361. PubMed ID: 34000372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent evolution of the epidemiological profile of extended-spectrum β-lactamase producing uropathogenic enterobacteria in Marrakech, Morocco].
    El Bouamri MC; Arsalane L; Kamouni Y; Berraha M; Zouhair S
    Prog Urol; 2014 Jun; 24(7):451-5. PubMed ID: 24861685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vital Signs: Containment of Novel Multidrug-Resistant Organisms and Resistance Mechanisms - United States, 2006-2017.
    Woodworth KR; Walters MS; Weiner LM; Edwards J; Brown AC; Huang JY; Malik S; Slayton RB; Paul P; Capers C; Kainer MA; Wilde N; Shugart A; Mahon G; Kallen AJ; Patel J; McDonald LC; Srinivasan A; Craig M; Cardo DM
    MMWR Morb Mortal Wkly Rep; 2018 Apr; 67(13):396-401. PubMed ID: 29621209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.